Introduction: To develop better cell therapy to combat cardiovascular disease (CVD), a greater number of cell markers or populations should be tested for their regenerative potentials. We applied single cell RNA-sequencing (scRNA-seq) analysis of multiple organs to identify attractive cell subsets for therapeutic angiogenesis.Methods: We revisited scRNA-seq datasets of various human organs. Transcriptomic data were normalized and analyzed for dimension reduction, cell clustering, and gene ontology. The screened cell population was sorted, cultured, and transplanted into a nude mice model of limb ischemia. Furthermore, AT of CVD patients (n=40) was evaluated for the cell subset by flowcytometry.Results: We analyzed three well-known sources of cell therapy including bone marrow, adipose tissue (AT), and umbilical-cord blood. After clustering, lineage negative mesenchymal cell clusters were compared their expression of pro/anti-angiogenic factors. Interestingly, AT showed the most prominent expression of both pro- and anti-angiogenic factors (Fig.A). Then, we divided AT stromal cells into pro- and anti-angiogenic clusters. From this clustering, 17 markers were screened as specific for pro-angiogenic cluster (Fig.B). Subsequently, we identified a receptor CD271 as top candidate for angiogenic cell isolation. CD271 cells showed enhanced angiogenic capacity in cell therapy experiments when compared to CD271cells. Furthermore, we detected long-term engraftment (PKH26) and increased number of proliferating host tissue cells using EdU labeling (Fig.C). Finally, we found CD271 cells were significantly reduced and deteriorated in CVD patients with insulin resistance or higher Lp(a) (Fig.D).Conclusions: CD271 cells from AT of metabolically healthy donors appears as an attractive for therapeutic angiogenesis. ScRNA-seq analysis is a potent tool to accelerate cell therapy field to find better cell populations and appropriate resources.